Peptide VIP : Protection intestinale, santé cérébrale et régulation immunitaire
Novo Pharma Research Team
Recherche Novo Pharma · synthèse de littérature révisée par les pairs
Peptide VIP : Protection intestinale, santé cérébrale et régulation immunitaire
Meta Description : Le peptide VIP (peptide intestinal vasoactif) soutient la guérison intestinale, la neuroprotection et l'équilibre immunitaire. Découvrez ses mécanismes, son utilisation dans le CIRS, le dosage et la recherche.
Références
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-1218.
- Harmar AJ, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166(1):4-17.
- Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol. 2012;166(1):42-50.
- Abad C, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003;124(4):961-971.
- Aton SJ, et al. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005;8(4):476-483.
- Bhatt DK, et al. VIP-mediated neuroprotection against glutamate excitotoxicity in cortical neurons. Neuropeptides. 2014;48(5):319-326.
- Gozes I, Bhatt DK. VIP: from anti-aging to Alzheimer's disease. J Mol Neurosci. 2019;68(3):436-443.
- Vaccarino FM, et al. VIP deficiency during brain development: relevance to autism. Ann Neurol. 2001;49(6):780-786.
- Delgado M, et al. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005;78(6):1327-1338.
- Shoemaker RC, et al. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013;5(3):396-401.
- Fernandez-Martin A, et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci. 2006;1070:276-281.
- Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease. FASEB J. 2003;17(8):944-946.
All compounds discussed and sold through Novo Pharma are intended strictly for laboratory and in-vitro research purposes. Products are not for human or animal consumption, not for use in food, cosmetics, or medicinal applications, and not for any therapeutic or diagnostic use.
The information on this page is provided for educational context and documents findings from published research. It is not medical advice, not a recommendation, and not a suggestion that any compound be used outside of a controlled research environment. Consult a qualified healthcare professional for any medical or health-related decision.
By purchasing, you confirm you are a qualified researcher, accept full responsibility for proper handling and disposal, and agree to use compounds in compliance with all applicable local, provincial, and federal laws.